Back to top

Myriad Genetics (MYGN) Catches Eye: Stock Jumps 6.9%

Read MoreHide Full Article

Myriad Genetics, Inc. (MYGN - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $27.23 to $31.51in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen a mixed track record when it comes to estimate revision of one increase and no decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Myriad Genetics currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is positive.

Myriad Genetics, Inc. Price

Investors interested in the Medical - Biomedical and Genetics industry may consider Acorda Therapeutics, Inc. (ACOR - Free Report) , which also has a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Is MYGN going up? Or down? Predict to see what others think: Up or Down

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Acorda Therapeutics, Inc. (ACOR) - free report >>

Myriad Genetics, Inc. (MYGN) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in